FCGBP

Summary

FCGBP (Fc gamma binding protein, HGNC:13572) is a protein-coding gene on chromosome 19q13.2, encoding IgGFc-binding protein (Q9Y6R7). May be involved in the maintenance of the mucosal structure as a gel-like component of the mucosa.

Located in extracellular exosome.

Source: NCBI Gene 8857 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 1,009 total
• MANE Select transcript: NM_003890

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13572
Approved symbol	FCGBP
Name	Fc gamma binding protein
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	FC(GAMMA)BP, FcgammaBP
Ensembl gene	ENSG00000275395
Ensembl biotype	protein_coding
OMIM	617553
Entrez	8857

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding_CDS_not_defined, 1 protein_coding

ENST00000595713, ENST00000616721

RefSeq mRNA: 1 — MANE Select: NM_003890 NM_003890

Canonical transcript exons

ENST00000616721 — 28 exons

Exon	Start	End
ENSE00003713265	39893922	39894495
ENSE00003714709	39891643	39892186
ENSE00003715984	39870216	39870415
ENSE00003717014	39899556	39899697
ENSE00003717687	39927059	39928306
ENSE00003717849	39876658	39877274
ENSE00003719099	39883305	39883446
ENSE00003720702	39913690	39914257
ENSE00003726191	39885673	39885872
ENSE00003727252	39879555	39879892
ENSE00003727787	39902243	39902837
ENSE00003727856	39905731	39906323
ENSE00003728087	39873224	39873795
ENSE00003729630	39915185	39915789
ENSE00003733052	39918072	39918642
ENSE00003733709	39875388	39875931
ENSE00003736302	39885991	39886585
ENSE00003738034	39924383	39924732
ENSE00003738329	39877663	39878236
ENSE00003741906	39866737	39867120
ENSE00003742369	39872078	39872651
ENSE00003742840	39901925	39902124
ENSE00003743865	39889479	39890071
ENSE00003744605	39892911	39893527
ENSE00003747553	39895806	39896143
ENSE00003747858	39863323	39863496
ENSE00003754112	39934564	39934626
ENSE00003754704	39863621	39863892

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 99.08.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2085 / max 62.2316, expressed in 36 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180927	0.1363	23
180928	0.0721	21

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	99.08	gold quality
right lobe of thyroid gland	UBERON:0001119	97.16	gold quality
duodenum	UBERON:0002114	96.71	gold quality
thyroid gland	UBERON:0002046	96.17	gold quality
left lobe of thyroid gland	UBERON:0001120	96.16	gold quality
gall bladder	UBERON:0002110	95.05	gold quality
rectum	UBERON:0001052	94.50	gold quality
transverse colon	UBERON:0001157	92.50	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.80	gold quality
small intestine	UBERON:0002108	91.29	gold quality
colonic epithelium	UBERON:0000397	89.46	gold quality
vermiform appendix	UBERON:0001154	85.64	gold quality
intestine	UBERON:0000160	84.73	gold quality
minor salivary gland	UBERON:0001830	83.98	gold quality
saliva-secreting gland	UBERON:0001044	83.62	gold quality
descending thoracic aorta	UBERON:0002345	82.94	gold quality
colon	UBERON:0001155	82.47	gold quality
right coronary artery	UBERON:0001625	82.11	gold quality
mucosa of stomach	UBERON:0001199	81.22	gold quality
right adrenal gland	UBERON:0001233	80.80	gold quality
right adrenal gland cortex	UBERON:0035827	80.20	gold quality
stomach	UBERON:0000945	79.36	gold quality
thoracic aorta	UBERON:0001515	78.68	gold quality
metanephros cortex	UBERON:0010533	78.67	gold quality
body of stomach	UBERON:0001161	78.58	gold quality
left adrenal gland	UBERON:0001234	78.13	gold quality
left adrenal gland cortex	UBERON:0035825	78.05	gold quality
ascending aorta	UBERON:0001496	77.72	gold quality
adrenal gland	UBERON:0002369	77.01	gold quality
placenta	UBERON:0001987	76.75	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	12097.62
E-MTAB-8410	yes	8461.01
E-GEOD-84465	yes	5789.64
E-MTAB-9906	yes	2878.67
E-MTAB-9435	yes	1983.81
E-MTAB-9543	yes	1868.61
E-CURD-46	yes	1701.41
E-MTAB-8495	yes	1423.26
E-MTAB-8221	yes	1388.52
E-GEOD-139324	yes	350.30
E-MTAB-8142	yes	75.85
E-MTAB-6142	no	28.55
E-GEOD-110499	no	6.38
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

11 targeting FCGBP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-6878-3P	99.24	64.23	920
HSA-MIR-6744-3P	99.22	64.41	972
HSA-MIR-4757-5P	99.12	64.51	981
HSA-MIR-3145-3P	98.85	69.07	2031
HSA-MIR-12125	98.59	67.54	1044
HSA-MIR-4720-3P	98.50	68.88	988
HSA-MIR-5579-3P	97.00	68.81	1111
HSA-MIR-3139	96.68	66.77	652
HSA-MIR-7973	96.48	65.54	502

Literature-anchored findings (GeneRIF, showing 16)

• The differentially expressed Fc gammaBP could reflect its potential role in prostate malignancy as well as an indicator for progression of the cancer. (PMID:17938577)
• The GCTM-5 epitope on the mucin-like glycoprotein FCGBP is a cell surface marker for the study of normal differentiation lineages, regeneration, and disease progression in tissues of endodermal origin. (PMID:22761039)
• Immunochemistry and clinicopathological results showed that the expression of NT5E and FcGBP in gallbladder adenocarcinoma is an independent marker for evaluation of the disease progression, clinical biological behaviors and prognosis. (PMID:24310606)
• FCGBP may be used as a new biomarker for diagnosis, prevention or treatment for lung cancer. (PMID:24452952)
• FCGBP, ubiquitous in vertebrates, has a conserved N-terminal domain. This domain is also present as an N-terminal sequence in a number of bacterial proteins. (PMID:27189557)
• Salivary TFF3-FCGBP might play a role in the innate immune defense of the oral cavity and that TFF3 might also bind to microbial glycans. (PMID:31658587)
• A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer. (PMID:33686968)
• IgGFc-binding protein in pregnancies complicated by spontaneous preterm delivery: a retrospective cohort study. (PMID:33731725)
• The IgGFc-binding protein FCGBP is secreted with all GDPH sequences cleaved but maintained by interfragment disulfide bonds. (PMID:34126068)
• FcGBP and VCAM-1 are ponderable biomarkers for differential diagnosis of alcoholic liver cirrhosis. (PMID:35245761)
• FCGBP Is a Promising Prognostic Biomarker and Correlates with Immunotherapy Efficacy in Oral Squamous Cell Carcinoma. (PMID:35733916)
• Role of the mucin-like glycoprotein FCGBP in mucosal immunity and cancer. (PMID:35936008)
• Fc fragment of IgG binding protein is correlated with immune infiltration levels in hepatocellular carcinoma. (PMID:36803544)
• [IgG Fc binding protein (FCGBP) as a prognostic marker of low-grade glioma and its correlation analysis with immune infiltration]. (PMID:37515334)
• Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. (PMID:38017206)
• Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment. (PMID:38396056)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:dkey-65b12.6	ENSDARG00000076830

Paralogs (19): CHRDL2 (ENSG00000054938), CHRD (ENSG00000090539), CHRDL1 (ENSG00000101938), TECTA (ENSG00000109927), VWF (ENSG00000110799), MUC5B (ENSG00000117983), KCP (ENSG00000135253), ZAN (ENSG00000146839), CRIM1 (ENSG00000150938), BMPER (ENSG00000164619), OTOGL (ENSG00000165899), VWCE (ENSG00000167992), VWC2L (ENSG00000174453), MUC6 (ENSG00000184956), OTOG (ENSG00000188162), VWC2 (ENSG00000188730), MUC2 (ENSG00000198788), MUC19 (ENSG00000205592), MUC5AC (ENSG00000215182)

Protein

Protein identifiers

IgGFc-binding protein — Q9Y6R7 (reviewed: Q9Y6R7)

Alternative names: Fcgamma-binding protein antigen

All UniProt accessions (1): A0A087WXI2

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the maintenance of the mucosal structure as a gel-like component of the mucosa.

Subunit / interactions. Interacts with the Fc portion of IgG and with MUC2.

Subcellular location. Secreted.

Tissue specificity. Mainly expressed in placenta and colon epithelium. Expressed in thyroid, and down-regulated in thyroid carcinomas. Present in serum, with higher levels in patients with various autoimmune diseases (at protein level).

Domain organisation. The N-terminal IgGFc-binding region is primate-specific.

RefSeq proteins (1): NP_003881* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR001007	VWF_dom	Domain
IPR001846	VWF_type-D	Domain
IPR002919	TIL_dom	Domain
IPR003645	Fol_N	Domain
IPR014853	VWF/SSPO/ZAN-like_Cys-rich_dom	Domain
IPR025615	TILa_dom	Domain
IPR035234	IgGFc-bd_N	Domain
IPR036084	Ser_inhib-like_sf	Homologous_superfamily
IPR050780	Mucin_vWF_Thrombospondin_sf	Family

Pfam: PF00094, PF01826, PF08742, PF12714, PF17517

UniProt features (99 total): disulfide bond 28, domain 25, sequence variant 23, sequence conflict 11, glycosylation site 9, signal peptide 1, chain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8QCI	X-RAY DIFFRACTION	2.2

Predicted structure (AlphaFold)

No AlphaFold model available for Q9Y6R7 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (28): 472–611, 494–649, 864–1003, 886–1040, 1252–1390, 1274–1428, 1673–1815, 1695–1853, 1704–1812, 2072–2211, 2094–2252, 2453–2591, 2475–2629, 2874–3016, 2896–3054, 2905–3013, 3273–3412, 3295–3453, 3654–3792, 3676–3830 …

Glycosylation sites (9): 75, 91, 1317, 1743, 2138, 2518, 3719, 4145, 4540

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 109 (showing top): JAEGER_METASTASIS_DN, GCANCTGNY_MYOD_Q6, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, KOYAMA_SEMA3B_TARGETS_UP, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, DELYS_THYROID_CANCER_DN, FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN, SANSOM_APC_TARGETS_DN, MODULE_88, KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION, TGGNNNNNNKCCAR_UNKNOWN, RYTTCCTG_ETS2_B, MODULE_6, DBP_Q6

GO Biological Process (0):

GO Molecular Function (2): extracellular matrix structural constituent (GO:0005201), protein binding (GO:0005515)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), Golgi lumen (GO:0005796), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
structural molecule activity	1
extracellular matrix	1
binding	1
Golgi apparatus	1
intracellular organelle lumen	1
external encapsulating structure	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1732 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FCGBP	MUC2	Q02817	866
FCGBP	TFF3	Q07654	834
FCGBP	ZG16	O60844	741
FCGBP	CLCA1	A8K7I4	649
FCGBP	PIGR	P01833	531
FCGBP	AGR2	O95994	497
FCGBP	GKN2	Q86XP6	465
FCGBP	NRCAM	Q92823	437
FCGBP	SERPINA1	P01009	423
FCGBP	MUC12	Q9UKN1	423
FCGBP	TFF2	Q03403	418
FCGBP	B4GAT1	O43505	404
FCGBP	CHURC1	Q8WUH1	404
FCGBP	NPTX2	P47972	401
FCGBP	MUC17	Q685J3	397

IntAct

23 interactions, top by confidence:

A	B	Type	Score
TFF3	FCGBP	psi-mi:“MI:0915”(physical association)	0.590
A2M	MUC2	psi-mi:“MI:0915”(physical association)	0.400
CLCA1	IGHG1	psi-mi:“MI:0915”(physical association)	0.400
FCGBP	MLH1	psi-mi:“MI:0915”(physical association)	0.370
FCGBP	TFAP2A	psi-mi:“MI:0915”(physical association)	0.370
TFAP2C	FCGBP	psi-mi:“MI:0915”(physical association)	0.370
DDX19B	IGLL5	psi-mi:“MI:0914”(association)	0.350
SCN2A	IGLL5	psi-mi:“MI:0914”(association)	0.350
GNG8	POTEF	psi-mi:“MI:0914”(association)	0.350
PPP2R2B	A2ML1	psi-mi:“MI:0914”(association)	0.350
GABPA	A2ML1	psi-mi:“MI:0914”(association)	0.350
RIPPLY3	A2ML1	psi-mi:“MI:0914”(association)	0.350
PTDSS1	IGLL5	psi-mi:“MI:0914”(association)	0.350
CCR1	UBA6	psi-mi:“MI:0914”(association)	0.350
NRSN1	IGLC7	psi-mi:“MI:0914”(association)	0.350
C18orf21	A2ML1	psi-mi:“MI:0914”(association)	0.350
PHF11	A2ML1	psi-mi:“MI:0914”(association)	0.350
SLC25A6	A2ML1	psi-mi:“MI:0914”(association)	0.350
LYPD6B	ZNF195	psi-mi:“MI:0914”(association)	0.350
MYCBP	A2ML1	psi-mi:“MI:0914”(association)	0.350
SULF2	IGKV2-29	psi-mi:“MI:0914”(association)	0.350
FCGBP		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS), FCGBP (Affinity Capture-MS)

ESM2 similar proteins: A2A863, A5A6I6, K9IMD0, O35632, O77698, O77811, O93429, O97490, P02787, P02788, P02789, P08071, P08582, P09571, P0DPD8, P0DPD9, P0DPE2, P12346, P14632, P16144, P19134, P20233, P22297, P24627, P26011, P27425, P31226, P56410, P79815, P79819, P80426, P80429, Q02942, Q12891, Q29443, Q29477, Q29545, Q501K5, Q64632, Q6AYF4

Diamond homologs: A1Z877, B5DFC9, H9JIQ1, O08523, O75443, O88322, P07911, P10493, P19218, P25291, P27590, P34501, P41950, P48733, P55259, Q0KHY3, Q14112, Q28833, Q3U492, Q5R5C1, Q5ZQU0, Q6ZWJ8, Q70E20, Q862Z3, Q8CJ69, Q8TER0, Q91X17, Q9D733, Q9IBG7, Q9Y6R7, Q9YH85, P02845, Q8N8U9, O88799, P57999, P87498, Q28983, Q8JZM4, Q8NFT8, Q91641

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1009 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	864
Likely benign	99
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4733 predictions. Top by Δscore:

Variant	Effect	Δscore
19:39863492:CATAA:C	acceptor_gain	1.0000
19:39863494:TAA:T	acceptor_gain	1.0000
19:39863497:C:CC	acceptor_gain	1.0000
19:39866736:CCCA:C	donor_gain	1.0000
19:39866761:CG:C	donor_gain	1.0000
19:39870210:ACT:A	donor_loss	1.0000
19:39870211:CTC:C	donor_loss	1.0000
19:39870212:TCA:T	donor_loss	1.0000
19:39870213:CACC:C	donor_loss	1.0000
19:39870214:A:AC	donor_gain	1.0000
19:39870214:A:AG	donor_loss	1.0000
19:39870215:C:CC	donor_gain	1.0000
19:39870215:C:G	donor_loss	1.0000
19:39870215:CCGG:C	donor_gain	1.0000
19:39872077:CGG:C	donor_gain	1.0000
19:39872649:GACC:G	acceptor_loss	1.0000
19:39872650:ACCT:A	acceptor_loss	1.0000
19:39872651:CCTG:C	acceptor_loss	1.0000
19:39872653:T:C	acceptor_loss	1.0000
19:39878233:TCAC:T	acceptor_gain	1.0000
19:39878234:CACC:C	acceptor_gain	1.0000
19:39879552:TACCC:T	donor_loss	1.0000
19:39879553:A:AC	donor_gain	1.0000
19:39879553:A:C	donor_loss	1.0000
19:39879553:AC:A	donor_gain	1.0000
19:39879554:C:CC	donor_gain	1.0000
19:39879554:CC:C	donor_gain	1.0000
19:39879554:CCCGG:C	donor_gain	1.0000
19:39879574:T:TA	donor_gain	1.0000
19:39879888:CGGGT:C	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000003921 (19:39912991 G>A), RS1000020183 (19:39916767 T>A), RS1000025526 (19:39881352 G>A,C), RS1000077835 (19:39881631 C>G), RS1000286362 (19:39867292 A>G), RS1000307163 (19:39874023 T>C), RS1000346493 (19:39922061 A>G), RS1000401390 (19:39867590 G>T), RS1000605147 (19:39933215 G>A,C), RS1000620511 (19:39868724 C>G,T), RS1000629159 (19:39869552 T>C), RS1000728287 (19:39868950 T>A,G), RS1000910678 (19:39869280 CAACA>C), RS1000947014 (19:39923167 G>A), RS1000976224 (19:39931056 C>G)

Disease associations

OMIM: gene MIM:617553 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003488_6	Response to fenofibrate (triglyceride levels)	4.000000e-06
GCST009391_337	Metabolite levels	2.000000e-06
GCST012335_19	Hodgkin’s lymphoma	5.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007681	triglyceride change measurement
EFO:0010433	triacylglycerol 56:6 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	decreases expression, increases expression, affects expression	4
Benzo(a)pyrene	decreases expression, decreases methylation, increases expression	3
bisphenol S	decreases expression, decreases methylation, affects cotreatment	2
Smoke	increases expression, decreases expression, increases abundance	2
Cadmium Chloride	increases expression, decreases expression, increases abundance	2
bisphenol F	affects cotreatment, decreases expression	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	increases expression	1
triphenyl phosphate	affects expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
terbufos	increases methylation	1
tris(2-butoxyethyl) phosphate	affects expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	increases expression	1
3,4,3’,4’-tetrachlorobiphenyl	affects expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
2-palmitoylglycerol	increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
licochalcone B	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Decitabine	increases expression	1
Zoledronic Acid	increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Cadmium	decreases expression, increases abundance	1
Dexamethasone	affects cotreatment, decreases expression	1
Fonofos	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.